Strong Medical Device Demand Drives Abbott's Q2 Revenue Up 4%, Prompting Raised Full-Year Profit Guidance

SmartCom Finance APP learned that Abbott (ABT.US), a leader in the U.S. healthcare sector, released its Q2 2024 earnings report before the U.S. stock market opened on July 18 and raised its full-year profit forecast. Strong growth in its medical device division helped Abbott surpass market expectations for the second quarter. Earnings data showed that Abbott's adjusted earnings per share for Q2 was $1.14, surpassing the analysts' average estimate of $1.10 per share and higher than $1.08 in the same period last year. Abbott’s total revenue in Q2 was approximately $10.38 billion, a year-over-year increase of 4%, in line with the analysts' average forecast.

Abbott's Medical Device Business Unit Achieved Revenue of up to $4.7 Billion in Q2, a Year-on-Year Increase of 10.2%. The double-digit revenue growth rate of this business unit was the main driver for Abbott’s performance growth, primarily benefiting from the strong sales performance of its Libre glucose monitoring system. In Q2, Abbott’s pharmaceuticals business unit achieved revenue of approximately $1.3 billion, a year-on-year increase of 0.6%; Abbott’s nutrition business unit achieved revenue of about $2.2 billion, a year-on-year increase of 3.5%; the medical diagnostics business unit achieved revenue of approximately $2.2 billion in Q2, a year-on-year decrease of 5.3%.

Medical Devices, Especially Those for Diabetics, Help Ease Concerns Over Litigation Related to the Company’s Infant Formula Products. In June, Abbott received approval from U.S. regulators for two new continuous glucose monitoring (CGM) systems, one of which is called Lingo, designed for non-diabetics. Prescription CGMs track blood sugar levels in real time and are typically used by insulin-dependent diabetic patients.

Abbott first announced the Lingo project two years ago, calling it "a new type of consumer biological wearable medical device." It builds on medical device technology initially developed for diabetes patients, allowing consumers to track health metrics such as blood sugar levels. According to a statement, Abbott hopes that Lingo will appeal to consumers who want to "better understand and improve their health."

In March, Dexcom, one of Abbott's competitors and a medical device manufacturer, also received approval for its over-the-counter CGM for non-diabetic individuals to use in their daily lives.

In the latest earnings forecast, the company stated in its earnings outlook on Thursday that it expects the adjusted earnings range for 2024 to be $4.61 to $4.71 per share, higher than its previous forecast of $4.55 to $4.70 per share.

Before the opening of the U.S. stock market, the company's share price once rose over 2.5% in pre-market trading. As of the close of the U.S. stock market on Wednesday, the stock has fallen more than 3% since the beginning of this year, significantly underperforming the S&P 500 Index, which has risen over 17%. However, the good news is that with the surge in热度of the "Trump trade" in the U.S. stock market and the shift in market focus from the seven major technology giants to low valuation targets, Abbott's share price has shown a significant rebound in recent days.

The consensus among traders and strategists is that a Trump victory would stimulate an inflationary mix trade benefiting from loose fiscal policy and greater protectionism. Therefore, the "Trump trade" primarily focuses on a stronger dollar, rising U.S. bond yields, and increases in bank, healthcare, and energy stocks.

As expectations of a Fed rate cut have significantly increased, market funds have started to shift towards companies with potentially substantial gains beyond the seven major tech giants. After all, giants like Nvidia, Microsoft, and Meta already have very high valuations. The market anticipates significant uncertainty that could arise from Trump's presidency and, in an environment of rate cuts, favors sectors with cheaper stock prices, strong fundamentals, and defensive characteristics—such as the lower-valued healthcare sector.